NPCE

NeuroPace, Inc.

$12.69

-3.28%
SectorHealthcareIndustryMedical DevicesCountryUnited States

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M-2.8%
3M-4.3%
YTD-18.7%
1Y+24.1%
52-week range—
Beta1.26
Full chart and returns against a benchmark

Q-Score

58/ 100

Quality against peers; 50 is the peer median.

Growth76
Risk57
Performance62
Valuation41
Profitability59
Leverage33
Sentiment71
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$100M+25.1%
Net income-$21.5M
Net margin-21.5%+12.5 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

NPCEIndustryP/E—29.61P/S4.073.49EV/EBITDA—18.38P/B36.663.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate$-0.09
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate